This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Athersys 過去の業績
過去 基準チェック /06
Athersysの収益は年間平均-12.5%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間33.8% 44%割合で 減少しています。
主要情報
-12.54%
収益成長率
2.99%
EPS成長率
| Biotechs 業界の成長 | 17.04% |
| 収益成長率 | -43.96% |
| 株主資本利益率 | n/a |
| ネット・マージン | -46,883.75% |
| 前回の決算情報 | 30 Sep 2023 |
最近の業績更新
Recent updates
Seeking Alpha • Oct 06
Athersys: Is Big Pharma Sleeping At The Wheel?
Summary Due to an extended downtrend in Athersys stock price due largely to a declining cash position, Athersys currently trades at a market cap near $24 million. The current valuation is miniscule when compared to valuations of other stem cell companies, especially when considering the strong IP portfolio of Athersys. Recent restructuring and cost-cutting, that included a 70% workforce reduction, will significantly reduce cash burn that previously approximated $20 million per quarter. The future of the company depends on an ability to fund the business through completion of the Masters 2, phase 3 trial for ischemic stroke. Few investors are ready to scoop up shares of Athersys (ATHX) stock after it has lost over 95% of its value over the last 52 weeks. However, with a deep stem cell IP portfolio, Athersys represents a huge opportunity with a reasonable chance of success that is not fully understood in the market. If you ask veteran biotech investors to provide names of leading stem cell companies, they may likely first point out that stem cell investing has been a high-risk, losing proposition for most investors. In any event, there are multiple companies that fit the general description of stem cell companies that are losing money and are under-financed in a difficult market for high-risk biotech. Compared to recent market volatility, the charts below illustrate mostly a downward trend over the last 52 weeks for 12 stem cell companies that could be compared to Athersys. StockCharts Beyond the charts, the table below provides some key financial data on stem cell companies that are characterized by little or no revenue, ongoing losses, and cash burn. To get an understanding of Athersys’s position in the stem cell sector, a comparison of some of the company’s peers may provide perspective. Compilation from author Of the above, Fate Therapeutics (FATE) has the largest market cap at $2.84 billion. Although Fate has revenue of $68 million, it is a clinical stage company that is developing therapies for cancer. Fate Therapeutics has seven cell products in development and, in addition, partnerships with Janssen Pharmaceuticals and Ono Pharma. Fate has an impressive pipeline of targets in their portfolio. However, all of their programs are in preclinical up to phase 1 development (source: Form 10K), which indicates a long development cycle ahead. Also noted in Table 1 above, cash burn from operations was $226.4 million in calendar year 2021 as the company raised $411 million from the sale of stock. Collaboration revenue in 2021 was $55.8 million. Fate utilizes pluripotent stem cells (embryonic) in a proprietary process to clone and expand cells for potential manufacture of an off-the-shelf cell product. For more information on Fate Therapeutics there are two interesting articles on Seeking Alpha published in June and August 2022. With a market cap of $911 million, Sangamo Therapeutics has several diverse platforms that go beyond the stem cell category under discussion, encompassing gene therapy, cell therapy, genome editing, and genome regulation. The Sangamo pipeline consists of one phase 3 program (Hemophilia A), three phase 1-2 programs, and 14 preclinical programs. Sangamo has been successful in collaborating with major partners in preclinical programs including Biogen, Kite, Novartis, Pfizer, and Takeda, and raising over $900 million in funds. While the company generated revenue or $114 million in the last 12 months, cash burn totaled $225 million in the same period. Third by market cap in the table illustration above, Century Therapeutics is developing cell therapies for cancer. Century utilizes genetically engineered CAR-T and CAR-NK therapies in combination with protein engineering, gene editing, and advanced proprietary manufacturing to target both solid tumor and hematological malignancies. Like Fate Therapeutics, Century utilizes induced pluripotent stem cells (iPSCs) in a proprietary process to maximize cell performance against malignancies. Century further states that the company has also developed capabilities to prevent rejection of its cell products in host immune systems. The company currently has five development programs, all in the discovery and preclinical stages (source: Form 10K). Unlike some of its peers in early-stage development, Century is establishing manufacturing capabilities in two facilities in 53,000 square feet of available space. In January 2022, Century entered into a collaboration agreement with Bristol-Myers Squibb (BMY) in two development programs. bluebird bio (BLUE), fourth by market cap, has been around since 1992, the longest of the group. bluebird’s pipeline includes product candidates for severe genetic diseases, betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease, and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. bluebird gained two FDA approvals in 2022. Zenteglo, a gene therapy for the treatment of the blood disorder β-thalassemia, was approved in August. Priced at $2.8 million per dose, Zenteglo was cited in the media as the most expensive drug worldwide. As an orphan drug, Zenteglo targets about 800 patients in the U.S. Although approved earlier in Europe, it has not been approved by insurance payors. On September 16, bluebird announced the approval of Skysona for a rare degenerative disease called cerebral adrenoleukodystrophy that affects boys ages 4-17. The retail price of the new therapy will be $3 million per dose. In spite of the foregoing, Bluebird expects to burn about $340 million in cash in 2022, as reported October 4 in the Wall Street Journal “Heard on the Street” column. With $218 million in cash at the end of Q2, it is apparent the company will need to raise cash. As quoted in the WSJ, “bluebird needs to raise money, and fast”. bluebird has collaboration agreements with Orchard Therapeutics Ltd, Forty-Seven, Inc., and Magenta Therapeutics. Of the companies in the comparison, Mesoblast (MESO) most closely resembles the product profile of Athersys, with one major distinction. Mesoblast product candidates are derived from mesenchymal stem cells, termed MSC, while Athersys utilizes multipotent adult progenitor cells (MAPC). According to scientists associated with Athersys, MAPC cells have a capacity to differentiate into diverse cell types that can be expanded much more rapidly in manufacturing than MSCs. MESO has two product candidates, Remestemcel-L and Rexlemestrocel-L, for four indications in phases 2-3 development, which includes one completed, but failed, a phase 3 trial of Remestemcel-L for the treatment of acute respiratory distress syndrome, abbreviated ARDS. Phase 3 results for Remestemcel-L were announced May 31 in which patients under age 65 (123 individuals) met trial endpoints, which were not met by patients 65 and older. MESO is currently awaiting feedback from the FDA on how to proceed in the ARDS indication. Meanwhile, MESO has three additional indications in phase 3 development nearing and/or reaching completion, and one phase 2 program. The most advanced program, that addresses Acute Graft Verses Host Disease (GVHD), has recently been submitted to the FDA for approval (source: various posts on the Mesoblast website). While Mesoblast has had some success in moving its programs forward, the company has not fared as well in collaborations. In December of 2021, the company announced that its key collaborative partner, Novartis, was terminating their partnership agreement with the company. In the comparison, there are obviously huge difference between the companies, including IP, indications, therapies, stage of development, and financial resources. Notably, current valuations are aligned with financial conditions rather than addressable markets. However, arguably, Athersys has the greatest addressable market with stroke that afflicts over 7 million people worldwide each year, as well as ARDS, and trauma indications currently in the clinical stage, as well as multiple preclinical indications, but with the lowest market cap of the group. It should also be noted that, when comparing the companies in Table 1, Athersys stands alone in targeting stroke and trauma, along with ARDS (that is also listed for Mesoblast). In addition, there are huge differences in the near-term cash requirements noted in the comparison. While Athersys was burning cash at a rate of about$20 million per quarter before restructuring, cash requirements will be decreased in the future. With the clinical trials for stroke and ARDS well underway, the company is approaching the finish line when viewing the long journey in the rearview mirror. As a bonus, a phase 2 trial for trauma, Matrics, is underway at little cost to the company as discussed below. Recapping recent developments, Athersys has two phase 3 trials running for stroke and ARDS. The ARDS trial has been temporarily suspended due to a current deficiency of funds. A phase 2 trial named Matrics for the treatment of trauma, funded mostly by the U.S. Department of Defense (MTEC) and UTHealth, continues to run at UT Health in Houston. Accordingly, Athersys has one of the most robust pipelines of all stem cell companies in terms of addressable market, as illustrated below: Athersys corporate presentation, used by permission In August Athersys scientists, Dr. Robert Mays and Dr. Sarah Busch, presented an overview of Athersys preclinical programs in a presentation titled “Rebalancing the Immune System: The MultiStem® Cellular Platform for Treating Disease and Injury” linked here. For current and future investors, time would be well-spent in listening to the one-hour presentation in evaluating the prospects for Multistem in areas beyond current trials including traumatic brain injury, spinal cord injury, hypoxic ischemic injury, multiple sclerosis, Parkinson’s disease, and others. The presentation covers an overview of evidence from animal studies that provide indication that Multistem cells work. As documented in the presentation, there have been 23 cellular therapies approved by FDA as of April 19, 2022, which include: autologous therapies (All CAR T variations) viral therapies (1 of which has since been placed on hold) fibroblast/collagen scaffolds for dermal treatments, allogeneic cord blood products, allogeneic product (thymus cells) for treating athymic children It should be noted in the foregoing that existing cell therapies are overwhelmingly autologous or allogeneic, meaning that they are either taken from a patient’s own cells or transplanted from a donor. While the cell therapies are tremendous benefits to the patients that receive them, they are difficult to scale. On the other hand, Athersys cell product Multistem can be scaled to hundreds-of-thousands doses from a single 100 mg bone marrow donation. The resultant cell product can be stored and dispensed as needed. In addition to proving the ability to expand stem cells robustly, Athersys management announced that the company had received FDA approval to manufacture Multistem in next-generation bioreactors for use in the Macovia (ARDS) and Matrics (trauma) clinical trials. This accomplishment puts the company well ahead of many of its peers. So, a lingering question for the value of the Athersys IP portfolio is efficacy of Multistem, as will be discussed below. The negatives The failure of the Healios Japanese Treasure trial for stroke to meet the primary endpoint announced May 20 was the main driver of the downward spiral of ATHX stock that was later accelerated with a deteriorating cash position at the company. The foregoing ultimately resulted in an approximately 70% workforce reduction at Athersys and an expense reduction plan that resulted in cutting back on trial programs. Further, extreme difficulty in raising capital continues to plague the business, which is documented in Q2 results, Form 10Q, pages 14-16. As of the report, the company had accounts payable of $27.7 million, that included about $20 million due to its current supplier of Multistem. In addition, while the company has no long-term debt, Athersys had only $13. 4 million in cash on the balance sheet as of the Q2 Form 10Q which raises serious questions about the company’s ability to fund operations and complete its phase 3 trials. Accordingly, the phase 3 trial for ARDS, Macovia, was later suspended, as announced on the Q2 earnings conference call. The events described above creates a dire perception of the company in the minds of some investors, which pushed the market cap to current low levels. The positives With a 70% workforce reduction and no long-term debt, $27 million in payables should not be a long-term deterrent to the fulfillment of the company’s mission to address ischemic stroke that affects 7.6 million people worldwide annually. When viewing Table 1 above, it becomes apparent that other companies are not pursuing therapies for stroke and trauma, huge unmet medical needs that have little hope for improvement otherwise. While some investors perceive reduced hope for Multistem after the Treasure trial results, there is compelling evidence of benefit for Multistem in treating ischemic stroke. As documented by Athersys in the May 20 report, the Treasure trial did not meet statistical significance of “excellent outcome” after one year of treatment with Multistem. However, Japanese patients treated in the study had a median age of 78 years, compared to a median age of 63 in the Masters 1, phase 2 trial in the U.S. completed by Athersys. Accordingly, it can be assumed that a measured number of the 206 patients were well into their 90s. Due to evidence of benefit for younger patients, the Treasure trial may offer a path to approval for Multistem in Japan where is has been given priority review status (Sakigake). Following the release of the Treasure data, Athersys hosted a panel discussion that featured six independent scientists who offered perspectives on the Treasure results and the potential of Multistem. While the participants have been associated with clinical trials for Multistem, they are independent scientists (shown below) who are focused solely on helping patients. An important takeaway from the panel discussion was strong evidence of benefit and positive trends for Multistem treatment of ischemic stroke, comparing it to what is currently available to treat patients. As several of the participants pointed out, little has changed in stroke therapy since 1996 when tPA (tissue Plasminogen Activator marketed by Genentech as Activase) was approved by the FDA. tPA is administered as a liquid to break up clots in stroke patients within a 4 ½ hour timeframe after the occurrence of stroke, with a result that only 10-15% of patients receive treatment. Then in 2008 mechanical thrombectomy was approved to physically remove clots within 6 hours of treatment. Both of the approved therapies have significant levels of risk for patients, including bleeding in the brain with tPA. Some of the participants expressed a belief that Multistem has the potential for a “seminal” event comparable to when tPA was approved in 1996, but with a much greater impact to treat many more patients. The first trial for tPA failed but later data from NINDS (National Institute of Neurological Disorders), was perceived to offer benefit, which lead to approval. Since the original jubilation over tPA, its use has been much less than anticipated. Athersys presentation, used by permission Summarizing some of the key points in full event, the participants were highly upbeat on the Treasure trial top line data and the prospects for Multistem. While pointing out the inadequacy of the Treasure trial primary endpoint of excellent outcome, they expressed the view that what is now needed is a successful trial in Masters 2 to convince naysayers. The full panel discussion can be accessed on a YouTube presentation.Seeking Alpha • Sep 23
Athersys extends exercise period of warrants in connection with recent offering
Athersys (NASDAQ:ATHX) has extended the exercise period of the warrants that were issued as part of a registered direct offering that closed on August 17, 2022. Pursuant to the amendment, the exercise period of the initial warrants has been extended from five years to seven years after the six-month anniversary of the closing date; the Standstill Period has been reduced from 180 days to 150 days; and term and amount of the participation right is reduced from twelve months to six months and from 30% to 20% in the aggregate of any offered securities, respectively. Purchasers are now required to participate in the event the company proposes to offer and sell shares of offered securities during the six months following the Closing Date to investors primarily for capital raising purposes. In return, the regenerative medicine company issued to the same warrant holder additional warrants that are exercisable for an aggregate of 2M shares of common stock and have an exercise price of $6.3850 for a seven-year period after the six-month anniversary of the date of issuance. ATHX shares gained 1.71% premarketSeeking Alpha • Aug 25
Athersys announces 1-for-25 reverse stock split
Athersys (NASDAQ:ATHX) announced Thursday it plans to execute a 1-for-25 reverse stock split of common shares, effective market close on Aug 26, 2022. That means every 25 shares of Athersys common stock issued and outstanding will be combined into 1 share. The stock is set to begin trading on a split-adjusted basis from market open on Aug. 29, 2022. Earlier: Athersys announces $12M securities offering分析記事 • Aug 16
One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher
Shareholders in Athersys, Inc. ( NASDAQ:ATHX ) may be thrilled to learn that the covering analyst has just delivered a...Seeking Alpha • Aug 12
Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents
Shares of micro-cap biotech Athersys (NASDAQ:ATHX) lost 8.8% to $0.26 in Friday late afternoon trading, after the company reported a quarterly loss that was in-line with estimates and a fall in cash and cash equivalents. ATHX after hours on Thursday posted Q2 GAAP EPS of -$0.09 which came in-line. It made revenue of $2.32M compared to no revenue last year, comprised entirely of contract revenue from collaboration partner Healios. The company said its cash and cash equivalents fell to $13.4M as of quarter-end, compared to $37.4M as of Dec. 31, 2021. The quarter was a tough one for Athersys (ATHX), with its Japanese ischemic stroke study for its MultiStem cell therapy failing to meet its main goal in May. Following that, in June, ATHX announced that it would lay off 70% of its workforce. The company also named Kasey Rosado as its interim CFO last week.Seeking Alpha • Aug 04
Kasey Rosado named interim CFO of Athersys
Kasey Rosado has been named interim CFO of regenerative medicine company Athersys (NASDAQ:ATHX). The appointment comes as the firm announced engagement with Ankura Consulting Group. As Senior Managing Director at Ankura, Ms. Rosado provides advisory support for dozens of companies, specializing in financial and operational turnarounds. She brings to Athersys over 18 years of financial, operational and leadership experience.Seeking Alpha • Jul 25
Athersys: Dead Man Walking
Athersys is running on fumes with cash burn that exceeds its resources. The withdrawal of its stock purchase agreement was a tough punch for a reeling contestant. Athersys has a valuable, partially derisked asset in MultiStem but it may be too little, too late for current shareholders. I last discussed Athersys (ATHX) in 04/2022's "Athersys - Hero Or Zero Opportunity". There are still prospects for each of these two antipodal results, hero or zero; the hero is however looking less likely for Athersys. In this article I examine its current untenable situation. I review how it got here and what I expect for its future. Athersys is running at the end of its financial string. Athersys' most recent (Q4, 2021) earnings call acknowledged its dire cash situation. In response to an analyst question asking for its strategy as Athersys approached the end of its cash runway, then CFO Macleod responded: Yes. So with a run rate -- or with a cash burn of between $17 million and $20 million, of course, we do have the ability to dial it up, dial it down. But you're correct, we have enough to get through at least the end of the second quarter [the current quarter, which as I write on 07/22/2022, already ended several weeks back]. As I had mentioned, we do have access to our equity line, which could provide financing. If the data does not lead to a successful partnership, we have explored other means of financing, which I don't really want to give the details just yet. We have not pulled the trigger on it. But suffice to say, we have not so far accessed the debt markets. And there are other possibilities that we're exploring. But our intention is to proceed with our discussions on the partnership. And we do anticipate the readout to be positive. I have italicized the blue and red statements, not in a political sense but insofar as their vagueness smacks of blue sky and red flags. Athersys' plan B as it runs out of cash is too ill-defined and uncertain to support an investment in Athersys. Now that its Aspire equity line is no more, Athersys' situation is ever more dire. CFO Macleod opens the second paragraph of his above response by referring to Athersys' equity line. As Athersys' share price has sunk well below the $0.50 minimum price required (10-K p. 43) for use of this line, it had become less and less of a lifeboat. Nonetheless, Aspire's decision to pull the line entirely removes the likelihood for negotiating a last ditch deal with its long time (since 2011) financing partner. The same 07/08/2022 8-K that announced termination of this financing source, announced more unsettling news; CFO Macleod left his employment on 06/30/2022. It also advised that CEO Camardo was filling in: ...as the Company’s principal financial officer and principal accounting officer while the Company searches for a new permanent Chief Financial Officer. Camardo is not receiving compensation for his added role. As I write midday on 07/22/2022, Athersys trades at $0.20; it carries a market cap of ~$57 million. Its trajectory has been awful as shown below: Data by YCharts In terms of ratings on Seeking Alpha, it has only the slimmest inkling of a pulse as shown below: Athersys' ratings (seekingalpha.com) Its sector ranking at 1156 out of 1157 says it all from the standpoint of financial metrics. Athersys is scraping along at the nether bottom of its sector's barrel. Athersys' MultiStem tribulations have been highly frustrating and seem to be ongoing. Athersys' MultiStem in treatment of stroke has shown exceptional promise in a most frustrating series of clinical trials. Athersys has proven itself to be a serial bungler. "Athersys: Stem Cell Opportunity For Risk Tolerant Investors" ("Opportunity") describes its travails in considerable detail. As described in Opportunity, its 2011 MASTERS ischemic stroke trial "NCT01436487" missed its primary endpoint. However Athersys determined that this was because of a design flaw in the study which included patients up to 2 days following the onset of a stroke. A 2015 study data review showed that patients who were treated within a narrower window had better outcomes. Athersys was unable to act on this insight until 2018 when it initiated MASTERS-2. The pandemic intervened causing enrollment delays. It was struggling to complete enrollment by close of 2021. In its Q2, 2022 corporate fact sheet, it reported that enrollment in MASTERS-2 was ongoing, expected to complete by the end of 2022 or "soon thereafter". Sadly as I write on 07/22/2022, the story moves to Japan. Athersys' partner Healios as discussed in Opportunity, has now leapt to the front of the story having completed its TREASURE trial while MASTERS-2 is still enrolling patients. Athersys has issued an 05/26/2022 slide deck overview of TREASURE results. The news is mixed. The trial showed substantial benefits for stroke victims; however it fell short of its primary outcome measure of "excellent outcomes". The slide below summarizes the situation: MultiStem TREASURE trial (seekingalpha.com) Healios' CFO Richard Kincaid is featured in an informative 8:25 presentation with its own slide deck including the following slide (discussed from 2:15-3:00/8:25): net-presentations.com TREASURE showed as statistically significant in 2 of 3 outcome measures, the Global Recovery and Barthel Index; the Excellent Outcome measure showed an improvement but it was not statistically significant. Healios' final slide (discussed from 6:10-7:26/8:25) gives a glimpse of MultiStem's path towards regulatory approval in Japan: net-presentations.com This slide shows that MultiStem has potential in Japan; it does not satisfy Athersys' urgent need for instant cash. The TREASURE results are disappointing; they do not, however, spell doom for MASTERS-2. Athersys expects a favorable outcome for its MASTERS-2 trial based on the read through below from the TREASURE trial: seekingalpha.comSeeking Alpha • May 04
Athersys: Focus On Stroke
Company has been focused on developing a viable treatment for stroke for nearly 20 years. Article will discuss chances for success in treating stroke with Phase 3 results to be reported in Japan this month. Company could offer colossal returns for high-risk tolerant investors. Based on the actions of insiders, there is strong evidence the company could be successful.Seeking Alpha • Apr 18
Athersys - Hero Or Zero Opportunity
On 04/11/2022, Athersys shares spiked after a long downward slide, soon they were back on the skids. Athersys' big dollar late-stage therapeutic candidates are highly attractive. Athersys' uncertain financial future will challenge its shareholder mettle to the core.Seeking Alpha • Jan 20
Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022
Company has a robust pipeline in late-stage clinical development largely unknown to investors. Enrollment for stroke phase 3 and ARDS trials is now complete in Japan and well underway in the U.S. A leader in stem cell technology, company has a market cap near $182 million, a fraction of many clinical, late-stage biotechs with lessor prospects. Multiple catalysts could multiply the share price in 2022.分析記事 • Dec 30
Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Nov 25
Athersys: COVID-ARDS Is The Company's Most Important Target
I covered Athersys' ischemic stroke trial earlier. The stock has fallen as a result of issues with this trial. However, Covid-induced ARDS is its most important indication, where it has market-leading positive data.Seeking Alpha • Aug 30
Athersys Shares Are Ready To Rumble Following Period Of Turmoil
Positive ARDS Results in Japan should lead to approval and revenues. Enrollment complete in 220 patient stroke study in Japan. Japan's progressive regenerative medicine approval regulations bode well for success. Athersys shares have not reflected the upside of recent developments.Seeking Alpha • Jul 29
Athersys: Subgroup Analysis As A Masterstroke
ATHX did what many biopharma do, they reinvented a failed trial as a success based on post-hoc subgroup analysis. However, the subgroup they chose makes scientific sense. Phase 3 topline data next year will decide the issue.分析記事 • May 28
Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Feb 27
Is Athersys (NASDAQ:ATHX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...収支内訳
収支内訳
Athersys の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -38 | 10 | 0 |
| 30 Jun 23 | 0 | -47 | 10 | 0 |
| 31 Mar 23 | 2 | -58 | 13 | 0 |
| 31 Dec 22 | 5 | -73 | 15 | 0 |
| 30 Sep 22 | 6 | -81 | 19 | 0 |
| 30 Jun 22 | 11 | -84 | 19 | -35 |
| 31 Mar 22 | 8 | -83 | 18 | 0 |
| 31 Dec 21 | 6 | -87 | 20 | 0 |
| 30 Sep 21 | 6 | -87 | 19 | 0 |
| 30 Jun 21 | 1 | -94 | 19 | 35 |
| 31 Mar 21 | 1 | -90 | 19 | 0 |
| 31 Dec 20 | 1 | -79 | 16 | 0 |
| 30 Sep 20 | 0 | -66 | 14 | 0 |
| 30 Jun 20 | 0 | -56 | 13 | 0 |
| 31 Mar 20 | 4 | -47 | 12 | 0 |
| 31 Dec 19 | 6 | -45 | 11 | 0 |
| 30 Sep 19 | 7 | -46 | 12 | 0 |
| 30 Jun 19 | 10 | -44 | 11 | 0 |
| 31 Mar 19 | 25 | -27 | 11 | 0 |
| 31 Dec 18 | 24 | -24 | 10 | 0 |
| 30 Sep 18 | 24 | -26 | 10 | 0 |
| 30 Jun 18 | 22 | -24 | 9 | 0 |
| 31 Mar 18 | 3 | -37 | 9 | 0 |
| 31 Dec 17 | 4 | -32 | 8 | 0 |
| 30 Sep 17 | 4 | -26 | 8 | 0 |
| 30 Jun 17 | 3 | -25 | 8 | 0 |
| 31 Mar 17 | 3 | -26 | 8 | 0 |
| 31 Dec 16 | 17 | -15 | 8 | 0 |
| 30 Sep 16 | 27 | -5 | 8 | 0 |
| 30 Jun 16 | 27 | -5 | 8 | 0 |
| 31 Mar 16 | 27 | 1 | 8 | 0 |
| 31 Dec 15 | 12 | -16 | 8 | 0 |
| 30 Sep 15 | 2 | -27 | 7 | 0 |
| 30 Jun 15 | 1 | -25 | 7 | 0 |
| 31 Mar 15 | 2 | -23 | 7 | 0 |
| 31 Dec 14 | 2 | -22 | 7 | 0 |
| 30 Sep 14 | 2 | -25 | 7 | 0 |
| 30 Jun 14 | 3 | -26 | 7 | 0 |
| 31 Mar 14 | 3 | -33 | 6 | 0 |
| 31 Dec 13 | 2 | -31 | 6 | 0 |
| 30 Sep 13 | 4 | -24 | 6 | 4 |
質の高い収益: ATHX.Qは現在利益が出ていません。
利益率の向上: ATHX.Qは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: ATHX.Qは利益が出ておらず、過去 5 年間で損失は年間12.5%の割合で増加しています。
成長の加速: ATHX.Qの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: ATHX.Qは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。
株主資本利益率
高いROE: ATHX.Qの負債は資産を上回っているため、自己資本利益率を計算することは困難です。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2024/09/25 18:05 |
| 終値 | 2024/09/25 00:00 |
| 収益 | 2023/09/30 |
| 年間収益 | 2022/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Athersys, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| James Molloy | Alliance Global Partners |
| Gregory Harrison | BofA Global Research |
| Adam Cutler | Canaccord Genuity |